Shares of Clarivate PLC (NYSE:CLVT – Get Free Report) have earned a consensus recommendation of “Reduce” from the seven ratings firms that are presently covering the company, Marketbeat reports. Three research analysts have rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $3.0167.
A number of equities research analysts have weighed in on the company. The Goldman Sachs Group decreased their target price on Clarivate from $2.90 to $2.60 and set a “neutral” rating for the company in a research report on Thursday, July 30th. Citigroup dropped their price objective on shares of Clarivate from $2.80 to $2.50 and set a “neutral” rating on the stock in a research note on Thursday, July 30th. Barclays reduced their price objective on shares of Clarivate from $2.50 to $2.00 and set an “underweight” rating for the company in a research note on Thursday, July 30th. Weiss Ratings restated a “sell (e+)” rating on shares of Clarivate in a research note on Wednesday, June 24th. Finally, Wall Street Zen lowered shares of Clarivate from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st.
Check Out Our Latest Report on Clarivate
Insider Transactions at Clarivate
Institutional Investors Weigh In On Clarivate
Hedge funds have recently bought and sold shares of the stock. Abel Hall LLC increased its stake in shares of Clarivate by 12.4% during the first quarter. Abel Hall LLC now owns 54,302 shares of the company’s stock worth $137,000 after acquiring an additional 5,972 shares during the period. Parallel Advisors LLC grew its position in shares of Clarivate by 94.2% in the first quarter. Parallel Advisors LLC now owns 13,786 shares of the company’s stock valued at $35,000 after purchasing an additional 6,687 shares during the last quarter. Royal Bank of Canada increased its position in Clarivate by 44.8% during the first quarter. Royal Bank of Canada now owns 32,818 shares of the company’s stock worth $83,000 after buying an additional 10,149 shares in the last quarter. Ancora Advisors LLC raised its stake in Clarivate by 12.3% in the 2nd quarter. Ancora Advisors LLC now owns 100,000 shares of the company’s stock valued at $216,000 after purchasing an additional 10,970 shares during the last quarter. Finally, Personal CFO Solutions LLC acquired a new position in shares of Clarivate in the first quarter valued at approximately $30,000. Hedge funds and other institutional investors own 85.72% of the company’s stock.
Clarivate Stock Performance
CLVT stock opened at $1.90 on Friday. Clarivate has a twelve month low of $1.66 and a twelve month high of $4.17. The business’s fifty day simple moving average is $2.05 and its two-hundred day simple moving average is $2.31. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -3.66 and a beta of 1.39. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 0.93.
Clarivate (NYSE:CLVT – Get Free Report) last issued its earnings results on Wednesday, July 29th. The company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.01. Clarivate had a negative net margin of 13.84% and a positive return on equity of 9.15%. The business had revenue of $587.30 million for the quarter, compared to the consensus estimate of $589.73 million. During the same period in the prior year, the firm earned $0.18 EPS. The company’s revenue for the quarter was down 5.5% compared to the same quarter last year. Analysts predict that Clarivate will post 0.67 earnings per share for the current year.
Clarivate Company Profile
Clarivate Plc (NYSE: CLVT) provides information, analytics and workflow solutions for organizations operating in research, academia, intellectual property and the life sciences. Its products are designed to help customers discover and evaluate research, manage intellectual-property portfolios, assess scientific and commercial opportunities, and support evidence-based decision-making.
The company’s offerings include Web of Science research and citation databases, InCites research analytics, Derwent patent information, Cortellis life-sciences intelligence, and CompuMark trademark and brand-protection solutions.
Further Reading
- Five stocks we like better than Clarivate
- Generac Plugs into Amazon for an $8B AI-Powered Deal
- Laser Focus: 2 Optical Stocks Lighting Up AI
- Aeluma’s Selloff Could Be Setting Up Its Next Big Move
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
Receive News & Ratings for Clarivate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarivate and related companies with MarketBeat.com's FREE daily email newsletter.
